Anagrelide or hydroxyurea, which one has fewer side effects and safety analysis

Anagrelide and Hydroxyurea are both drugs used to treat essential thrombocythemia (ET) or other myeloproliferative diseases, but there are certain differences in side effects and safety. The main mechanism of action of anagrelide is to inhibit megakaryocyte maturation, thereby reducing platelet production, while hydroxyurea inhibits bone marrow cell proliferation by inhibiting DNA synthesis. This difference in mechanism leads to different side effect profiles between the two, and also affects clinical patient selection.

First, from the perspective of hematological side effects, hydroxyurea may cause leukopenia and red blood cell reduction, anemia, or low platelets, while anagrelide has relatively few hematological side effects, mainly manifesting as mild thrombocytopenia. Therefore, for patients with fragile hematology or at risk of anemia, anagrelide is generally superior to hydroxyurea in terms of hematological safety. However, anagrelide may cause palpitations, increased heart rate, or mild edema in some patients, and they need to pay attention to their cardiovascular health.

Secondly, in terms of non-hematological side effects, long-term use of hydroxyurea may increase the risk of skin ulcers, pigmentation, oral ulcers, etc., and may also increase the probability of secondary malignant tumors. Relatively speaking, the non-hematological side effects of anagrelide are mild, mainly headache, fatigue, indigestion or mild palpitations, and the incidence of serious side effects is lower than that of hydroxyurea. Therefore, from a long-term safety perspective, anagrelide is more likely to be tolerated in some patient groups.
Thirdly, from the perspective of safety management in clinical application, anagrelide requires regular monitoring of cardiovascular indicators, such as electrocardiogram and blood pressure, while hydroxyurea relies more on routine blood work and liver and kidney function monitoring. Both require dosage adjustment based on patient response, but the dosage adjustment space of anagrelide is relatively flexible. For some patients who are intolerant to hydroxyurea or are at risk of long-term medication, anagrelide provides a safer alternative.
In summary, anagrelide has generally fewer side effects than hydroxyurea, especially in terms of hematology and long-term safety. However, attention needs to be paid to cardiovascular-related adverse reactions. Which drug to choose clinically should be determined by the doctor after comprehensive evaluation based on the patient's blood indicators, cardiovascular health status and long-term medication needs, in order to achieve a balance between maximum efficacy and minimum risk.
Reference: https://www.drugs.com/